We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DuPont Closes $1.8B Aramids Sale to Arclin, Shifts Growth Focus
Read MoreHide Full Article
Key Takeaways
DuPont sold its Aramids unit to Arclin for about $1.8B, including Kevlar and Nomex brands.
DD received $1.2B cash, a $300M note and a 16% Arclin stake valued near $325M.
Move aims to lift margins, cut cyclicality, and sharpen focus on higher-return businesses for Dupont.
DuPont de Nemours Inc. (DD - Free Report) has completed the divestiture of its Aramids business to Arclin in a deal valued at approximately $1.8 billion, marking a pivotal milestone in its strategic transformation. The transaction includes the transfer of leading high-performance fiber brands such as Kevlar and Nomex, which are widely used across defense, industrial safety and aerospace applications.
DuPont received roughly $1.2 billion in pre-tax cash proceeds, subject to customary adjustments, along with a $300 million note receivable and a non-controlling equity stake in Arclin valued at about $325 million, representing roughly 16% ownership. The company had already classified the Aramids segment as discontinued operations starting in the third quarter of 2025 to ensure that its financials no longer impact continuing operations.
The divestiture is expected to improve DuPont’s margin profile and reduce earnings volatility tied to cyclical end markets, while also strengthening its balance sheet and providing additional flexibility for capital allocation. The transaction further highlights DuPont’s disciplined approach to portfolio optimization as it sharpens its focus on innovation-driven, higher-return businesses while still retaining upside potential through its minority stake in Arclin.
Shares of DD are down 21.3% in the past year against the industry’s 25.2% growth.
Image Source: Zacks Investment Research
DD’s Zacks Rank & Other Key Picks
DD currently carries a Zacks Rank #1 (Strong Buy).
The Zacks Consensus Estimate for CMP’s current fiscal-year earnings is pegged at 89 cents per share, indicating a 285.4% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters while missing twice, with an average surprise of 35%.
The Zacks Consensus Estimate for JMPLY’s current fiscal-year earnings stands at $4.34 per share, implying a 13.9% year-over-year increase. Shares of JMPLY have surged 70% over the past year.
The Zacks Consensus Estimate for AHKSY’s current fiscal-year earnings is pegged at $1.38 per share, indicating a 7.8% year-over-year increase. Shares of AHKSY have surged 56.2% over the past year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
DuPont Closes $1.8B Aramids Sale to Arclin, Shifts Growth Focus
Key Takeaways
DuPont de Nemours Inc. (DD - Free Report) has completed the divestiture of its Aramids business to Arclin in a deal valued at approximately $1.8 billion, marking a pivotal milestone in its strategic transformation. The transaction includes the transfer of leading high-performance fiber brands such as Kevlar and Nomex, which are widely used across defense, industrial safety and aerospace applications.
DuPont received roughly $1.2 billion in pre-tax cash proceeds, subject to customary adjustments, along with a $300 million note receivable and a non-controlling equity stake in Arclin valued at about $325 million, representing roughly 16% ownership. The company had already classified the Aramids segment as discontinued operations starting in the third quarter of 2025 to ensure that its financials no longer impact continuing operations.
The divestiture is expected to improve DuPont’s margin profile and reduce earnings volatility tied to cyclical end markets, while also strengthening its balance sheet and providing additional flexibility for capital allocation. The transaction further highlights DuPont’s disciplined approach to portfolio optimization as it sharpens its focus on innovation-driven, higher-return businesses while still retaining upside potential through its minority stake in Arclin.
Shares of DD are down 21.3% in the past year against the industry’s 25.2% growth.
DD’s Zacks Rank & Other Key Picks
DD currently carries a Zacks Rank #1 (Strong Buy).
Other top-ranked stocks in the Basic Materials space include Compass Minerals International, Inc. (CMP - Free Report) , Johnson Matthey Plc (JMPLY - Free Report) and Asahi Kasei Corporation (AHKSY - Free Report) . CMP carries a Zacks Rank of #1, while JMPLY and AHKSY have a Zacks Rank of #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for CMP’s current fiscal-year earnings is pegged at 89 cents per share, indicating a 285.4% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters while missing twice, with an average surprise of 35%.
The Zacks Consensus Estimate for JMPLY’s current fiscal-year earnings stands at $4.34 per share, implying a 13.9% year-over-year increase. Shares of JMPLY have surged 70% over the past year.
The Zacks Consensus Estimate for AHKSY’s current fiscal-year earnings is pegged at $1.38 per share, indicating a 7.8% year-over-year increase. Shares of AHKSY have surged 56.2% over the past year.